氟普拉嗪 | 76716-60-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 氟普拉嗪
• 中文别名: 氟哌乙脲
• 英文名称: Fluprazine
• 英文别名: 2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethylurea
• CAS: 76716-60-4
• 化学式: C₁₄H₁₉F₃N₄O
• 分子量: 316.32
• InChiKey: CHQKHXJPWDSTPY-UHFFFAOYSA-N

物化性质

• 沸点：
  431.6±45.0 °C(Predicted)
• 密度：
  1.265±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  61.6
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• Phenyl piperazine derivatives having analgetic activity
  申请人：DUPHAR INTERNATIONAL RESEARCH B.V

  公开号：EP0048043A1

  公开（公告）日：1982-03-24

  It has been found that the group of phenyl piperazine derivatives of formula 3 of the formula sheet and the salts thereof have a strong analgetic activity. The compounds can be prepared in a manner known for analogous compounds and be processed to the usual compositions.

  研究发现，式表中式 3 的苯基哌嗪衍生物及其盐类具有很强的镇痛活性。 这些化合物可以用已知的类似化合物的方法制备，并加工成通常的成分。
• Pre-column for preconcentrating substances to be chromatographed, as well as device for a liquid chromatography system and coupling member for said device
  申请人：DUPHAR INTERNATIONAL RESEARCH B.V

  公开号：EP0092860A1

  公开（公告）日：1983-11-02

  The invention relates to a pre-column of pressure-resistant material for preconcentrating at elevated pressure substances to be chromatographed, which column consists of a vessel-shaped body which narrows internally towards the two ends (3, 5) and has means (6) for sealing connections, upstream to an inlet tube for the liquid to be preconcentrated and downstream to a separating column. The invention also relates to a device for a liquid chromatography system, comprising one or more pre-columns (45, 46, 47), optionally one or more separating columns, and a coupling member (22), and to a coupling member (22) for said device.

  本发明涉及一种耐压材料的预柱，用于在高压下预浓缩待色谱物质，该柱由一个容器形体组成，容器形体内部向两端（3、5）收窄，并有密封连接装置（6），上游连接待预浓缩液体的入口管，下游连接分离柱。 本发明还涉及一种用于液相色谱系统的装置，该装置包括一个或多个预柱（45、46、47）、可选的一个或多个分离柱和一个耦合部件（22），以及用于所述装置的耦合部件（22）。
• Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
  申请人：Counts David F.

  公开号：US10463611B2

  公开（公告）日：2019-11-05

  The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a water-soluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours.

  本公开提供了一种用于口服的每日一次水溶性药用活性制剂。在某些实施方案中，该组合物包括掺入小颗粒中的水溶性药用活性有机化合物，每个颗粒都有一个水溶性药用活性有机化合物或其可接受盐的核心，该核心与药学上可接受的药物结合聚合物可逆结合。组合物的核心由不溶性透水膜包围，该膜能够延迟其中的药用活性化合物的溶解，并延长药用活性化合物的释放时间。在某些实施方案中，本发明的制剂可将药用活性有机化合物的释放时间延长约 3 小时至约 8 小时，从而能够制备半衰期为约 16 小时至约 21 小时的任何药用活性化合物的缓释制剂。
• Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
  申请人：Pfizer Inc.

  公开号：US10952972B2

  公开（公告）日：2021-03-23

  The present disclosure generally relates to nanoparticles comprising an endo-lysosomal escape agent, a nucleic acid, and a polymer. Other aspects include methods of making and using such nanoparticles.

  本公开一般涉及由内溶酶体逃逸剂、核酸和聚合物组成的纳米颗粒。其他方面包括制造和使用这种纳米颗粒的方法。